Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
SMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series.
Sci Prog
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Despite advances in multimodal cancer therapy, such as combining radical surgery with high-intensity chemoradiotherapy, for SMARCB1/INI-1-deficient sinonasal carcinoma (SDSC), the prognosis of patients remains poor. Immunotherapy is gaining increasing popularity as a novel treatment strategy for patients with SMARCB1/INI-1-deficient tumors. Herein, we report on the management of three patients with SDSC who received PD-1/PD-L1 inhibitor therapy as a part of multimodal therapy based on surgery and chemoradiotherapy.
View Article and Find Full Text PDF. Extract Attenuates Inflammation and Oxidative Damage in Cisplatin-Induced Cardiotoxicity in Rats by Promoting M2 Macrophage Polarization.
Mediators Inflamm
January 2025
Faculty of Medical Sciences, Department of Genetics, University of Kragujevac, Kragujevac, Serbia.
L. fruits and leaf extracts have a broad range of immunomodulatory, anti-inflammatory, and antioxidant effects; however, their effects on cardiac protection have not been investigated. The study aims to test the biological activity of L.
View Article and Find Full Text PDFCombined RET and MEK Inhibition as a Treatment for Fusion-Positive NSCLC With Acquired Fusion: A Case Report.
JTO Clin Res Rep
November 2024
Department of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.
fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a fusion treated with selpercatinib.
View Article and Find Full Text PDFSafety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis.
PeerJ
January 2025
Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
Objective: To evaluate the safety profiles of EZH2-targeted inhibitors in cancer treatment, focusing on treatment-related adverse events (TRAEs) across various clinical trials.
Methods: We conducted a systematic review and meta-analysis using data from clinical trials involving EZH2 inhibitors reported up to May 31, 2024. Databases searched included PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.
Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma.
Front Immunol
January 2025
The Second Clinical Medical College of Jinan University, Department of Radiotherapy, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Background: Immunotherapy represents a major breakthrough in malignant tumor treatment in recent years. Anti-PD-1 immunotherapy has significantly prolonged Event-free Survival (EFS) in Nasopharyngeal Carcinoma (NPC). However, its potent anti-tumor effects can also attack normal tissues and organs, leading to immune-related adverse effects (irAE), with the thyroid being one of the most commonly affected organs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!